Extramedullary involvement of B-cell Acute Lymphoblastic Leukemia (EM-ALL) is a rare occurrence, characterized by dismal outcome and the absence of a defined and shared therapeutic approach. In the landscape of innovative compounds, inotuzumab ozogamicin (IO) is a promising drug, whose mechanism of action relies on the killing of CD22 positive leukemic cells, through the delivery, after cell binding, of a molecule of calicheamicin.
Titolo: | Inotuzumab ozogamicin is effective in relapsed/refractory extramedullary B acute lymphoblastic leukemia | |
Autore/i: | Bertamini, Luca; Nanni, Jacopo; Marconi, Giovanni; Abbenante, Mariachiara; Robustelli, Valentina; Bacci, Francesco; Matti, Antonella; Paolini, Stefania; Sartor, Chiara; Monaco, Silvia Lo; Fontana, Maria Chiara; De Polo, Stefano; Cavo, Michele; Curti, Antonio; Martinelli, Giovanni; Papayannidis, Cristina | |
Autore/i Unibo: | ||
Anno: | 2018 | |
Rivista: | ||
Digital Object Identifier (DOI): | http://dx.doi.org/10.1186/s12885-018-5026-x | |
Abstract: | Extramedullary involvement of B-cell Acute Lymphoblastic Leukemia (EM-ALL) is a rare occurrence, characterized by dismal outcome and the absence of a defined and shared therapeutic approach. In the landscape of innovative compounds, inotuzumab ozogamicin (IO) is a promising drug, whose mechanism of action relies on the killing of CD22 positive leukemic cells, through the delivery, after cell binding, of a molecule of calicheamicin. | |
Data stato definitivo: | 2019-02-22T12:00:41Z | |
Appare nelle tipologie: | 1.01 Articolo in rivista |
File in questo prodotto:
File | Descrizione | Tipo | Licenza | |
---|---|---|---|---|
s12885-018-5026-x.pdf | Versione (PDF) editoriale | Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY) | Open Access Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.